[Skip to Navigation]
Comment & Response
December 30, 2020

Macular Abnormalities Associated With 5α-Reductase Inhibitor—Reply

Author Affiliations
  • 1Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
JAMA Ophthalmol. 2021;139(2):252-253. doi:10.1001/jamaophthalmol.2020.5774

In Reply We would like to thank Barbara and Patricia Burgos-Blasco for their interest in our article.1 As they mentioned, 5α-reductase inhibitor (5-ARI) dosage varies depending on diagnosis. Dutasteride is used as a treatment for benign prostate hyperplasia (BPH) and androgenic alopecia at a dose of 0.5 mg per day, and finasteride is used at a dose of 5 mg per day for BPH and 1 mg per day for androgenic alopecia.2,3 We described in the Table of our article1 the diagnosis for each case as well as the treatment duration and cumulative dosage, through which the daily dosage can be obtained. We could not develop a dose-toxicity curve from the limited number of cases.

Add or change institution